teladoc glp-1 💊 For the past few years, receptor agonists have dominated the conversation around weight management. This month, the MHRA approved the UK's first oral GLP-1 receptor agonist tablet for… GLP-1 Discontinuation Misconception in Obesity

Description

The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron

Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease: Results from the LEADER trial

Generally, the best candidates are women under the age of 60 or within 10 years of menopause onset who have bothersome symptoms, and don't have contraindications to systemic hormone therapy (which include a history of blood clots and certain types of cancer, like breast cancer), according to Faubion

Maybe not so much anymore

For example, in the STEP 1 (Semaglutide Treatment Effect in People with Obesity) trial, all participants received individual counseling every four weeks to support adherence to a reduced-calorie diet (500 kcal/day deficit from estimated energy expenditure) and to encourage at least 150 minutes per week of physical activity, such as walking